Posted by Michael Wonder on 11 Oct 2021
Minister for Health announces HSE approval to reimburse Zolgensma (onasemnogene abeparvovec) as part of a joint BeNeLuxA collaboration
8 October 2021 - Following the first joint agreement on the price of a drug between Belgium, Ireland and the Netherlands, the HSE has decided to approve the gene therapy drug Zolgensma (onasemnogene abeparvovec) for reimbursement in the treatment of spinal muscular atrophy for patients who meet the specified criteria.
The Minister for Health, Stephen Donnelly TD, has welcomed the HSE's decision, which represents a very significant development for the State as it is the first time Ireland has agreed to fund a drug for rare diseases in partnership with other countries in the BeNeLuxA Initiative.
